You're viewing a public preview of AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs Sign up free to access full investment history, financials, executives & more
Sign Up Free Log In

AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs

Inactive
Vienna,  1030,  Austria
Sector: Life Science Entity: Private
Merged AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs merged into AC Immune SA in 2021
2
Transactions
Sign up to view
$59M
Deal Value
Sign up to view
About AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs is a privately held company operates in the Life Science sector. Private market activity associated with the company includes investment from AC Immune SA. The company is headquartered in Vienna. AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs appears in Acquity Data's private market intelligence platform.
Investors
Current Investors
AC Immune SA ••••••••
Past Investors
•••••••• ••••••••
View Full Investor List
Sign up to see all current & past investors with deal dates and transaction details
Sign Up Free Log In
Investment Details
2 Transactions
Trans. IDInvestment DateExit DateInvestor(s)Deal Size (M)Seller(s)
Access 2 Transactions
Sign up to view the full investment history — dates, deal sizes, investors & sellers
Sign Up Free Log In
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs M&A Activity
# Company Transaction Date Close Date Sector Country
View M&A Acquisitions
Sign up to explore the full acquisition & merger history
Sign Up Free Log In
Key Executives & Professionals
View Executives & Professionals
Sign up to access board members, senior management & key contacts
Sign Up Free Log In
Frequently Asked Questions
What does AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs do?
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs is a privately held company operates in the Life Science sector. Private market activity associated with the company includes investment from AC Immune SA. The company is headquartered in Vienna. AFFiRiS - Specific Active I
Where is AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs headquartered?
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs is headquartered in Vienna, Austria.
When was AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs founded?
Founded year information for AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs is available on AcquityData.
What sector is AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs in?
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs operates in the Life Science sector.
Who are the investors in AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs?
Current investors in AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs include AC Immune SA. Sign up to AcquityData to view full investor details, deal dates and transaction history.
How many M&A transactions has AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs been involved in?
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs has 2 transactions tracked on AcquityData. Sign up to view full investment history including dates, deal sizes, investors and sellers.

Unlock the full AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs profile

Ownership & Investors M&A History Financials Key Executives Advisors & Lenders

Access AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs's complete ownership history, M&A activity, investors, advisors and executives in one connected platform.

Start Free Trial